Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) EPS (Weighted Average and Diluted) (2020 - 2021)

Historic EPS (Weighted Average and Diluted) for Astrazeneca (AZNCF) over the last 9 years, with Q2 2021 value amounting to $743.75.

  • Astrazeneca's EPS (Weighted Average and Diluted) fell 3923.27% to $743.75 in Q2 2021 from the same period last year, while for Jun 2021 it was $743.75, marking a year-over-year decrease of 3923.27%. This contributed to the annual value of -$1360.0 for FY2014, which is 4122.53% down from last year.
  • According to the latest figures from Q2 2021, Astrazeneca's EPS (Weighted Average and Diluted) is $743.75, which was down 3923.27% from $0.0 recorded in Q1 2021.
  • Astrazeneca's 5-year EPS (Weighted Average and Diluted) high stood at $1223.9 for Q2 2020, and its period low was $0.0 during Q1 2021.